Completed PHASE4 INTERVENTIONAL 3-arm NCT02060552

Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels

Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation

Sponsor: Tongji Hospital

Interventions Colchicine Diacerein Febuxostat

Updated 6 times since 2017 Last updated: May 7, 2014 Started: Jan 31, 2013 Primary completion: Mar 31, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02060552, this PHASE4 trial focuses on Primary Gout and remains completed. Sponsored by Tongji Hospital, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tongji Hospital

Data source: Tongji Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China